Rohto Pharmaceutical Co.,Ltd. (TYO:4527)

Rohto Pharmaceutical Balance Sheet

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Cash & Equivalents	75,839	77,161	89,210	79,951	72,791	52,964
Cash & Short-Term Investments	75,839	77,161	89,210	79,951	72,791	52,964
Cash Growth	3.01%	-13.51%	11.58%	9.84%	37.44%	16.90%
Receivables	66,517	69,880	69,115	60,656	51,682	47,865
Inventory	63,163	61,580	46,657	41,062	33,527	27,925
Other Current Assets	9,558	9,258	9,777	8,577	6,306	4,317
Total Current Assets	215,077	217,879	214,759	190,246	164,306	133,071
Property, Plant & Equipment	88,364	90,451	68,607	66,182	62,839	49,790
Long-Term Investments	38,909	46,649	43,731	32,629	27,471	27,425
Goodwill	32,932	47,494	2,285	2,564	2,954	4,014
Other Intangible Assets	34,720	8,575	6,932	6,997	6,338	3,521
Long-Term Deferred Tax Assets	-	3,975	3,869	5,371	5,297	4,606
Long-Term Deferred Charges	98	99	-	-	-	-
Other Long-Term Assets	18,226	2	2	1	2	2
Total Assets	428,326	421,875	346,175	309,677	274,627	225,790
Accounts Payable	20,997	22,056	21,123	18,718	16,269	11,330
Accrued Expenses	20,307	24,364	25,720	24,362	19,354	25,208
Short-Term Debt	6,843	7,035	5,304	4,177	8,033	2,312
Current Income Taxes Payable	3,847	6,963	6,643	6,230	3,185	6,138
Other Current Liabilities	32,845	34,190	28,297	26,675	24,647	11,483
Total Current Liabilities	84,839	94,608	87,087	80,162	71,488	56,471
Long-Term Debt	42,039	43,188	5,190	7,516	13,350	5,787
Long-Term Deferred Tax Liabilities	-	2,081	1,597	1,173	1,450	639
Other Long-Term Liabilities	15,540	8,789	2,720	2,645	1,177	2,831
Total Liabilities	144,183	150,436	99,142	94,600	90,797	69,179
Common Stock	6,504	6,504	6,504	6,504	6,504	6,504
Additional Paid-In Capital	-	-	4,516	5,292	5,787	5,661
Retained Earnings	238,871	228,442	209,399	184,005	162,195	145,511
Treasury Stock	-9,939	-9,939	-4,939	-4,938	-4,936	-4,936
Comprehensive Income & Other	31,303	35,087	30,843	18,706	8,737	3,167
Total Common Equity	266,739	260,094	246,323	209,569	178,287	155,907
Minority Interest	17,404	11,345	710	5,508	5,543	704
Shareholders' Equity	284,143	271,439	247,033	215,077	183,830	156,611
Total Liabilities & Equity	428,326	421,875	346,175	309,677	274,627	225,790
Total Debt	48,882	50,223	10,494	11,693	21,383	8,099
Net Cash (Debt)	26,957	26,938	78,716	68,258	51,408	44,865
Net Cash Growth	-2.87%	-65.78%	15.32%	32.78%	14.58%	18.03%
Net Cash Per Share	117.73	117.69	344.04	298.33	224.69	196.09
Filing Date Shares Outstanding	225.96	225.96	228.14	228.14	228.14	228.14
Total Common Shares Outstanding	225.96	225.96	228.14	228.14	228.14	228.14
Working Capital	130,238	123,271	127,672	110,084	92,818	76,600
Book Value Per Share	1180.45	1151.04	1079.71	918.60	781.48	683.38
Tangible Book Value	199,087	204,025	237,106	200,008	168,995	148,372
Tangible Book Value Per Share	881.05	902.91	1039.31	876.69	740.75	650.35

Source: S&P Global Market Intelligence. Standard template. Financial Sources.